IJR News

TRexBio prices $117M IPO, Nasdaq trading expected — 5dTRexBio priced its IPO at $14.00 a share for 8,333,334 shares, expecting about $116.7 million, with Nasdaq trading under TRXB.

0

FireFly Robotics Files for Proposed Nasdaq Direct ListingTech — Oct 7, 2026FireFly Robotics filed to list up to 27.1 million existing shares on Nasdaq as FFLY on Oct. 7, 2026, raising no proceeds after withdrawing a prior $29.3 million IPO plan.

0

Asian shares mixed after Nasdaq hits new record — Oct 6, 2026Nasdaq rose 1.1% to a record close as Asian shares mixed; Aramco's Amin Nasser said the oil supply cushion is scarily thin, with less than 10 percent of reserves available.

0

Jared Kim Investors should watch corporate earnings closely now since inflation and rate uncertainty might limit any further market gains.

DayOne Data Centers files for Nasdaq IPO amid AI infrastructure interest — Oct 5, 2026DayOne Data Centers filed for a Nasdaq IPO as DODC on October 5, 2026; Renaissance Capital estimates the offering could raise about $3.0 billion.

+2

Elena Vasquez Timing an IPO now makes sense before rates or competition cool things off.

WISeSat.Space Begins Nasdaq Trading as SAIQ After Columbus Merger — Oct 1, 2026WISeSat.Space completed its business combination with Columbus Acquisition Corp. and began trading on Nasdaq under the ticker SAIQ on October 2. The newly listed company plans to expand secure satellite communications and IoT connectivity, drawing on WISeQey’s cybersecurity and digital identity technologies.

+2

Marcus Bell This merger with Columbus should help WISeSat expand its satellite IoT reach using solid cybersecurity tools.

AP Top 25 College Football TeamsRankingCollege football fans argue endlessly over which programs deserve the top spots in the AP Poll based on wins, schedule strength, and legacy.

European stocks post modest gains as French fiscal worries persistFinance — Oct 5, 2026European stocks rose modestly Tuesday as Brent fell below $100 after Nasdaq's AI-led record; Le Pen warned France was heading toward debt default.

0

Nicole Hardy Brent falling below 100 is helpful for energy costs but the modest European gains show investors are still cautious on fiscal risks.

US Stocks Open Higher, Oil, Yields EaseFinance — Oct 6, 2026U.S. stocks opened modestly higher Friday, with the Nasdaq leading gains as oil prices eased on reduced concerns about Middle East supply disruptions. Telecom shares bucked the broader advance amid competition concerns following SpaceX’s spectrum acquisition.

0

International Bancshares Plans Texas Exchange ListingFinance — Oct 6, 2026Texas Capital Bancshares began trading on the Texas Stock Exchange after moving its primary listings from Nasdaq, with its tickers expected to change in November. International Bancshares also plans to move its listing to TXSE, starting Oct. 19 under ticker IBOC, as both companies cite their deep Texas ties.

0

Moody’s Tops 2027 RiskTech100, Nasdaq Ranks Second — Sep 24, 2026Nasdaq climbed from fifth to second in Chartis RiskTech100 2027 with 14 category awards, up from five, after more than 900 vendors were evaluated.

0

Maya Lindstrom Moody's five-year streak at the top shows how hard it is for others to match their risk tech depth.

Reports Show Short Positions Shifting Across Markets — Oct 7, 2026Nasdaq-reported short interest across its listed securities rose to 23.09 billion shares at Sept. 30, up from 22.52 billion two weeks earlier, while days to cover fell. Separate reports noted a sharp percentage increase in short interest for the Harbor Long-Short Equity ETF and growing leveraged crypto short bets; Sweden’s largest disclosed stock shorts also shifted, with Electrolux posting the biggest increase and AAK the biggest decrease.

0

Lumen to shift stock and Qwest notes from NYSE to Nasdaq — Sep 25, 2026Lumen plans to move its common stock and Qwest subsidiary notes from the NYSE to Nasdaq, with trading expected to begin there Oct. 6 under the same ticker symbols. The company says the move aligns its listing with its AI-focused enterprise networking strategy and will not affect operations, finances, reporting obligations, or require action from shareholders.

+2

Jared Kim Switching exchanges for an AI strategy feels like a pointless shuffle if shareholders gain nothing from it.

Most Influential Women in World HistoryYourlist — RankingFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.

Paramount Skydance plans to move Class B shares listing to NYSE — Sep 25, 2026Paramount Skydance plans to move its Class B shares from Nasdaq to the New York Stock Exchange, with Nasdaq trading set to end around October 5 and NYSE trading to begin October 6. The shift comes as the company advances its planned Warner Bros. transaction and prepares a related warrant distribution for eligible shareholders.

+3

Dana Whitfield Moving the Class B shares to NYSE lines up well with the Warner Bros deal and could bring steadier trading.

ADARx Raises $446 Million in Upsized IPO — Sep 25, 2026ADARx Pharmaceuticals raised $446 million in an upsized IPO at $17 a share, the top of its range, and began Nasdaq trading under ADRX with an AbbVie private placement.

0

Chris Dalton Starting Nasdaq trading at 17 dollars feels like a steady launch for a company still in development.

Nasdaq Hits Record as Chip Stocks Rally — Sep 21, 2026U.S. stocks climbed on Monday as oil prices slipped, easing Treasury yields and renewed optimism around artificial intelligence supported broad gains across the S&P 500, Nasdaq, and Dow. The rally was underscored by tech and AI-related momentum, with market sentiment also shaped by high-profile discussions between Trump and Xi and ongoing geopolitical developments.

0

Singapore’s US Stock Trading Push Draws Limited Interest — Sep 23, 2026SpaceX SDRs traded about $2.3 million on SGX through Sept. 18—0.0007% of Nasdaq volume. Chris Forbes called the rollout "anticlimactic."

+2

Maya Lindstrom Investors will stick with direct US trading until these SDRs offer tighter spreads and real volume during Asian hours.

Toy Story vs ShrekYourlist — VS BattleThe toy box vs the swamp: two animation revolutions, one inevitable playground argument.

Global Equity Funds Draw $34.76B Amid AI Demand — Oct 2, 2026Investors poured money into U.S. and global equity funds as AI optimism and softer-than-expected U.S. inflation helped offset rising Treasury yields; U.S. equity funds drew $20.6 billion and global funds $34.76 billion in the week through September 30. Technology funds nonetheless saw outflows, while the J.P. Morgan Nasdaq Equity Premium Income ETF attracted about $756 million over five days.

+1

Tom Gallagher The softer inflation data clearly helped offset those rising yields and kept equity buying strong.

Accelevation Plans $720 Million IPO, $5.4B Valuation — Sep 22, 2026Accelevation seeks up to $720 million in a U.S. IPO at $20-$24 a share, implying as much as about $5.4 billion valuation, with Nasdaq ticker ACCV.

0

Rachel Meyers Raising 720 million at that price point shows they think demand is strong right now.

Nvidia-Backed Iambic Files for U.S. IPO — Sep 21, 2026Nvidia-backed Iambic filed for Nasdaq IPO as IAM after raising $461.8 million, same day it unveiled an AbbVie AI drug-discovery collaboration.

+2

Marcus Bell With 461 million already raised plus AbbVie ties, this IPO could help Iambic advance those early trials effectively.

Accelevation Prices $540 Million IPO Below Range — Sep 29, 2026Data center infrastructure maker Accelevation Holdings priced its IPO at $18 per share, below its previously indicated $20-to-$24 range, raising $540 million through sales of 30 million shares, most of them by Olympus Partners-affiliated shareholders. The stock opened below the IPO price on Nasdaq, while Accelevation said its share of the proceeds would go toward repaying debt, IPO costs and general corporate purposes.

0

Live Oak Acquisition VI Closes $230 Million IPOBusiness — Sep 22, 2026Live Oak Acquisition Corp. VI raised $230 million in its Nasdaq IPO, including the full exercise of the underwriters’ over-allotment option, and placed the proceeds in trust. The blank-check company intends to pursue a business combination in any industry.

0

Oura Indefinitely Postpones Planned IPOBusiness — Sep 25, 2026Oura’s planned Nasdaq IPO has reportedly drawn orders for about four times the 50 million shares on offer, despite a difficult market for new listings. The $40–$44-per-share offering could raise up to $2.2 billion and value the smart-ring maker at about $14.1 billion, or roughly $15 billion on a fully diluted basis.

0

May Mobility Plans $1.4B SPAC Public Listing — Sep 16, 2026May Mobility struck a $1.4B SPAC deal with ACP Holdings to list on Nasdaq as MAY by end of 2026, with up to $337M in proceeds and 550,000-plus rides already done.

+3

Dana Whitfield With that many rides already done, May Mobility looks like one of the more serious AV companies going public.

Wall Street Rallies Near Record as Oil, Yields Ease — Sep 21, 2026U.S. stocks rose toward record highs as oil prices pulled back and Treasury yields eased, with the S&P 500, Dow and Nasdaq all advancing and AI-linked shares contributing to gains. The market remains buoyed by improving oil-market dynamics amid Middle East tensions, though oil remains elevated above pre-war levels.

+3

Tom Gallagher The AI names leading the way is no surprise, but oil staying above pre-war levels still feels like a real risk hanging over this rally.

ADARx Plans $350 Million IPO, AbbVie Stake — Sep 21, 2026ADARx Pharmaceuticals plans a $350 million IPO by issuing 21.9 million shares at $15-$17 each, with AbbVie investing up to $100 million for about 4.9% of the company, valuing it around $1.8 billion and listing on Nasdaq as ADRX. The biotech focuses on siRNA therapies with three clinical-stage programs and two advanced preclinical programs, led by onvuzosiran in Phase 3 for hereditary angioedema, with pricing anticipated the week of September 21, 2026.

+3

Chris Dalton The $350 million raise at that valuation feels ambitious even with three clinical programs underway.